Andrew J. Rae, MBA – President, CEO and Director

Mr. Rae has spent a decade in the biotechnology industry, most recently as CFO with Ability Biomedical Corporation (Irvine CA, Vancouver BC), acquired by Medarex, Inc. in 2004. Mr. Rae has also served as Vice President, Finance & Corporate Affairs at Active Pass Pharmaceuticals (Vancouver BC). During his tenure at Active Pass and Ability Biomedical Mr. Rae raised approximately $20M in venture financing, engaged in a successful cross-border M&A; transaction, and played a significant role in shaping multiple business development deals. Prior to his operational experiences, Mr. Rae served as Biotechnology Equities Analyst, Goepel Shields & Partners (now Raymond James Canada), covering Canadian biotechnology stocks including Angiotech Pharmaceuticals, QLT Inc. and ID Biomedical. He currently sits on the Board of Directors for Liponex Inc., a Canadian, TSE-listed biopharmaceutical research company.  Mr. Rae holds a B.Sc. from the University of Western Ontario and an MBA from Simon Fraser University.

John G. Clement, PhD- Chief Technical & Development Officer and Director

Dr. Clement possesses over twenty years of experience in preclinical and clinical drug development, project management, and product acquisition. Most recently Dr. Clement served as Director, Business Development at QLT Inc., one of Canada’s largest biotechnology companies and developer of Visudyne®, a  $500M+ product used to treat age-related macular degeneration. Dr. Clement has also served as Director, Extramural Research/Associate Director, Biochemical Pharmacology & Toxicology at Biochem Pharma Inc., known as the pioneer of the AIDS drug 3TC.  He was also research scientist & manager with Department of National Defence (DND) and a Research Scientist with CIBA-Geigy Canada Ltd. During his tenure with DND he held various scientific leadership / management positions and was responsible for the development of a new antidote for nerve agent poisoning (HI-6). He possesses a PhD from the University of Western Ontario and has published over 60 scientific articles.

Dr. Peter Hnik, MD, MHSc – Chief Medical Officer

Dr. Hnik received his medical degree from the Medical Faculty of Charles University of Prague in 1981.  After practicing for years at the Eye Clinic of the Charles University Hospital where he performed surgery and consultation in glaucoma and neuro-ophthalmology, Dr. Hnik later joined the Eye Clinic of the University of British Columbia as part of the glaucoma research group.  He received his Master of Health Sciences degree from the University of British Columbia in 1999.  Prior to joining iCo Therapeutics, Dr. Hnik served as Associate Director of Clinical Research with QLT Inc., playing a critical role in designing and directing Visudyne clinical trials in AMD and diabetic retinopathy.  He was also heavily involved in the publication, in-licensing and pharmacovigilance activities for Visudyne.  Dr. Hnik is a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA) and the Drug Information Association (DIA).

W. John Meekison, BA, CIM – Chief Financial Officer and Director

Mr. Meekison is a veteran investment banker specializing in life sciences at Loewen Ondaatje McCutcheon, Haywood Securities, Dlouhy Merchant and PI Securities. As a financier, Mr. Meekison has raised in excess of $500 million in equity capital for various biotechnology companies such as StressGen Biotechnologies, ID Biomedical, Acorda Therapeutics, Inex Pharmaceuticals, Xenon Pharmaceuticals, Nortran Pharmaceuticals (now Cardiome) and BioMS Medical Corp.  As CFO for a TSE listed company developing a novel clinical diagnostic platform, Mr. Meekison supervised all public reporting functions, human resources, accounting and budgeting, raising equity capital, renegotiating the Company’s existing line of credit, reviewing corporate strategy, and led M&A; discussions. Mr. Meekison received his BA from the University of British Columbia and is a Certified Investment Manager.

Santa Jeremy Ono, PhD – Chief Scientific Officer

Professor Ono, a leading authority in the fields of immunology and ophthalmology, joined iCo Therapeutics in July 2005 as Chief Scientific Officer.  Dr. Ono also holds a university appointment as Vice Provost for Academic Initiatives and Deputy to the Provost at Emory University.  He most recently served as teh Cumberlege Professor of Biomedical Science and later as the GlaxoSmithKline Professor of Ocular Immunology at the University College London from 2001 to 2006 where he was the Chair of Immunology, UCL-Institute of Ophthalmology, Moorfields Eye Hospital (the world’s first and largest eye research and treatment centre).  Past appointments include Assistant Professor of Medicine, Pathology & Biology at Johns Hopkins University, and Associate Professor & Director of the Immunity, Inflammation and Transplantation Group at the Schepens Eye Research Institute, Harvard Medical School.

Professor Ono has directed multiple research and development programs, many of which have been in partnership with biotechnology and pharmaceutical companies.  Professor Ono received degrees from the University of Chicago (BA) and McGill University (PhD) and was a Helen Hay Whitney Fellow at Harvard University.  He serves on many editorial boards, is involved with numerous professional societies and associations, and has more than eighty publications to his credit.  Among his many honors, he was elected International Fellow of the American Academy of Asthma, Allergy and Immunology, Fellow of the Royal Society of Medicine, and received the Pharmacia International Award in Allergy Research.